The Change Of Serum Cytokines Before And After Transcatheter Arterial Chemoembolization And Its Significance In Hepatocellular Carcinoma

ObjectiveTo investigate the predict value of serum cytokines in prognosis of hepatocellular carcinomaafter transcatheter arterial chemoembolization by detecting cytokines before and aftertranscatheter arterial chemoembolization and analyzing the association with survival.MethodsThirteen unresectable hepatocellular carcinoma patients without antitumor treatment underwenttranscatheter arterial chemoembolization with Doxorubicin(30～60mg),Lipiodol (5～30ml) andgelatin sponge embolized tumor-feeding artery. We collected blood samples of patients beforeand 4-6 weeks after transcatheter arterial chemoembolization . And then we applied Luminexliquid-chip method to detect the concentration of thirty six kinds of candidate cytokines ,including: IL-1α,IL-1β,IL-1ra,IL-2,IL-4,IL-5,IL-6,IL-7,IL-8,IL-10,IL-12p40,IL-12p70,IL-13,IL-15,IL-17A,IL-17F,IFN-γ,TNF-α,TNF-β,G-CSF,GM-CSF,GRO-α,ENA-78,IP-10,MCP-1,MCP-3,MIP-1α,MIP-1β,RANTES,VEGF,BLC,Eotaxin,FGF-basic,Leptin,NGF,PDGF-BB. And then,analyze with Wilcoxon rank test for thechange of serum cytokines and Kaplan-Meier for survival.ResultsTwenty one kinds of cytokines,including IL-1α,IL-2,IL-5,IL-6,IL-7,IL-12 p40,IL-12p70,IL-15,IL-17A,IL-17F,INF-γ,G-CSF,ENA-78,IP-10,MCP-3,MIP-1β,VEGF,RANTES,Leptin,Eotaxin,NGF,can be detected in serum . G-CSF,IL-1α,IL-17A,RANTES and IL-6 were significantly lower after transcatheter arterial chemoembolization (P<0.05). Log-rank test showed that median survival in patients withΔG-CSF,ΔIL-1α,ΔRANTES> 0.3 is longer than with≤0.3, but the differences were not statistically significant(P> 0.05). Fifteen kinds of cytokines, including IL-1β,IL-1ra,IL-4,IL-8,IL-13,IL-10, TNF-α,TNF-β,GM-CSF,GRO-α,MCP-1,MIP-1α,BLC,FGF-basic,PDGFBB,wereout of detecting.Conclusion: RANTES,IL-1α,G-CSF,Leptin and VEGF maybe predict the prognosis inhepatocellular carcinoma with transcatheter arterial chemoembolization. The concentration ofIL-2 and IL-12 is low in hepatocellular carcinoma , which can be the basis for cytokines therapy.IL-1ra,IL-6 inhibitor,Leptin inhibitor,INF-γmay be novel drug for hepatocellular carcinoma.